SCHEMBL8937376

SCHEMBL8937376

COc1cccc(/C(=C/C(=O)O)c2ccc(Cl)cc2)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.48
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 6/20 0.44
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
GPR55 Q9Y2T6 1/20 0.44
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 4/20 0.42
TP53 P04637 1/20 0.40
MGLL Q99685 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937521 1.00 LMNA (0.48) LMNAALDH1A1GAANPC1MAPT
SCHEMBL8937382 1.00 LMNA (0.48) LMNAALDH1A1GAANPC1MAPT
SCHEMBL8999190 0.87 GRM5 (0.48) LMNAALDH1A1GAANPC1SMN1; SMN2
SCHEMBL5191943 0.84 CA12 (0.49) LMNAALDH1A1GAANPC1MAPT
SCHEMBL1008454 0.81 HPGD (0.47) LMNAALDH1A1GAANPC1MAPT
SCHEMBL30070832 0.78 POLB (0.51) LMNAALDH1A1MAPTSMN1; SMN2HPGD
SCHEMBL8937609 0.78 ALDH1A1 (0.54) LMNAALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL8937763 0.78 ALDH1A1 (0.54) LMNAALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL8937613 0.78 ALDH1A1 (0.54) LMNAALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL23393319 0.77 RAB9A (0.55) LMNAALDH1A1GAANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed